OpenAI announces life sciences-focused AI model "GPT-Rosalind" to improve drug discovery efficiency

OpenAI introduced GPT-Rosalind, a reasoning model built to support drug discovery and life science research.

The model is designed to speed up literature review, hypothesis generation, experiment planning, and data analysis.

Access is limited to qualified U.S. companies and is being rolled out as a research preview through ChatGPT, Codex, and the API.

The move could streamline early-stage R&D, but strict access controls remain important to prevent misuse.